Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.
Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.
In the PEMPHIX study, a double-blind, double-dummy, active-comparator, parallel arm study in patients requiring oral corticosteroids, patients were randomized to receive either rituximab plus a placebo or mycophenolate mofetil plus a placebo for 52 weeks along with steroids, with the aim of tapering the steroid dose to 0 by week 24.
The primary end point at week 52 was the percentage of participants who achieved sustained complete remission without treatment failure; the study met this end point, with 40.3% of patients treated with rituximab, versus just 9.5% of patients treated with mycophenolate mofetil, achieving sustained complete remission without steroids for 16 weeks or more (P = .0001).
Secondary end points also favored rituximab, says Genentech: Patients treated with the biologic had lower cumulative oral corticosteroid doses, fewer flares, a greater likelihood of sustained complete remission, a lower likelihood of flares, and greater improvements in quality of life. Adverse events were consistent with the known profile of rituximab.
The results were presented in a late-breaking oral presentation during the 28th Congress of the European Academy of Dermatology and Venereology in Madrid, Spain.
The FDA first approved the brand-name rituximab for PV in 2018 on the basis of a different phase 3 study, the Ritux 3 trial, which showed that rituximab plus corticosteroids was superior to corticosteroids alone as first-line treatment for patients with PV. As a results of the findings, the International Bullous Disease Consensus Group reached an international consensus to recommend rituximab and corticosteroids as first-line therapy for moderate to severe PV.
The newly reported data could help Genentech and its innovator drug stay ahead of biosimilar competition, at least in the PV market; notably, the 2 currently FDA-approved biosimilar rituximab products, Pfizer’s Ruxience and Celltrion’s Truxima, are not approved to treat PV. The biosimilars both have so-called “skinny labels” due to patent protections and exclusivities for the reference drug. Neither drug has yet announced a launch date for the US marketplace.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates
February 27th 2024Samsung Bioepis provided multiple updates on its biosimilar projects, including a new partnership for its aflibercept biosimilar candidate as well as regulatory news in the European Union and Republic of Korea.
FDA Approves 10th Adalimumab Biosimilar, Simlandi
February 24th 2024After receiving 3 complete response letters, Alvotech has officially received US approval for its adalimumab biosimilar (AVT02; Simlandi), making it the first approval for the company, the 10th biosimilar to reference Humira, and the third interchangeable adalimumab biosimilar.